

<https://doi.org/10.59298/NIJBAS/2026/7.2.2329>

Diabetes-Associated Decline in Antioxidant Networks: Consequences for Immune Surveillance and Tissue Integrity

Ivan Mutebi

Department of Pharmacognosy Kampala International University Uganda
Email: ivan.mutebi@studwc.kiu.ac.ug

ABSTRACT

Diabetes mellitus, a metabolic disorder characterized by chronic hyperglycemia, exerts broad systemic effects that extend beyond glucose dysregulation. Central to these effects is an imbalance between reactive oxygen species (ROS) production and the body's antioxidant defense systems, leading to persistent oxidative stress. In diabetic conditions, increased ROS generation arises from glucose auto-oxidation, mitochondrial dysfunction, activation of alternative metabolic pathways, and formation of advanced glycation end products (AGEs), while antioxidant networks such as superoxide dismutase, catalase, glutathione peroxidase, and non-enzymatic antioxidants are simultaneously compromised. This redox imbalance contributes to cellular and molecular damage, impairs immune surveillance by disrupting innate and adaptive immune responses, and undermines tissue integrity through endothelial dysfunction, chronic inflammation, and genomic instability. Moreover, oxidative stress accelerates diabetic complications such as neuropathy, nephropathy, retinopathy, and macrovascular disease. Understanding these mechanisms has profound implications for prevention, early detection, and therapeutic interventions. Emerging strategies aimed at restoring antioxidant capacity and modulating immune function may mitigate the progression of diabetic complications.

Keywords: Diabetes mellitus, oxidative stress, antioxidant defenses, immune surveillance, tissue integrity.

INTRODUCTION

Diabetes mellitus comprises a heterogeneous group of metabolic disorders characterized by persistent hyperglycemia resulting from impaired insulin secretion, defective insulin action, or a combination of both [1-5]. Type 1 diabetes is primarily caused by autoimmune-mediated destruction of pancreatic β -cells, leading to absolute insulin deficiency, whereas type 2 diabetes is driven by insulin resistance coupled with relative insulin insufficiency [6-9]. Despite their distinct etiologies, both forms of diabetes converge on shared downstream metabolic abnormalities that profoundly affect cellular redox balance, immune competence, and tissue architecture. One of the most prominent biochemical hallmarks of diabetes is oxidative stress, defined as a sustained imbalance between the generation of reactive oxygen species and the capacity of antioxidant defense systems to neutralize them [10-14]. Under physiological conditions, controlled ROS production plays an essential role in cellular signaling, host defense, and metabolic regulation [15-20]. However, in diabetes, excessive ROS accumulation overwhelms antioxidant mechanisms, resulting in oxidative damage to lipids, proteins, and nucleic acids. This oxidative burden contributes not only to metabolic dysfunction but also to immune dysregulation and progressive tissue injury [21-26]. The decline in antioxidant networks in diabetes is multifactorial, involving both increased

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

ROS generation and impaired antioxidant synthesis, recycling, and enzymatic activity [27-29]. Hyperglycemia-driven metabolic flux through alternative biochemical pathways amplifies oxidative stress, while chronic inflammation further suppresses endogenous antioxidant responses. The resulting redox imbalance disrupts immune surveillance by altering leukocyte function and inflammatory signaling, increasing susceptibility to infections and impairing immune resolution [30-33]. Simultaneously, oxidative damage compromises the structural and functional integrity of vascular, neural, renal, and connective tissues, accelerating the development of diabetes-associated complications [34-38]. Understanding the molecular mechanisms linking hyperglycemia to antioxidant network failure is therefore critical for elucidating the pathogenesis of diabetic complications. This section outlines the biochemical and cellular processes responsible for antioxidant decline in diabetes and highlights their integration with inflammatory and metabolic stress pathways.

2. Mechanisms Underlying Antioxidant Network Decline in Diabetes

2.1 Hyperglycemia and ROS Overproduction

Chronic hyperglycemia is the principal driver of excessive ROS production in diabetes. Elevated intracellular glucose concentrations activate multiple biochemical pathways that directly or indirectly increase oxidative stress [39-45]. Glucose auto-oxidation occurs when excess glucose reacts with molecular oxygen, generating superoxide radicals and other reactive intermediates [46-50]. In parallel, increased flux through the polyol pathway converts glucose to sorbitol via aldose reductase, a process that consumes NADPH. Because NADPH is essential for regenerating reduced glutathione, this diversion compromises one of the cell's most important antioxidant systems [51-54]. Hyperglycemia also promotes the formation of advanced glycation end products through non-enzymatic reactions between glucose and proteins, lipids, or nucleic acids [55-58]. AGEs accumulate in tissues and bind to their cellular receptor, RAGE, triggering intracellular signaling cascades that enhance ROS generation and pro-inflammatory gene expression [59-62]. In addition, mitochondrial metabolism is profoundly altered in diabetes. Excess glucose-derived substrates increase electron flow through the mitochondrial respiratory chain, leading to electron leakage and enhanced formation of superoxide radicals [63-64]. These combined mechanisms create a sustained intracellular oxidative environment that exceeds physiological redox signaling and promotes cellular injury.

2.2 Impairment of Antioxidant Defenses

In healthy cells, oxidative stress is counterbalanced by a coordinated antioxidant network comprising enzymatic and non-enzymatic components [65]. Enzymatic antioxidants include superoxide dismutase, which converts superoxide radicals into hydrogen peroxide; catalase and glutathione peroxidase, which further detoxify hydrogen peroxide into water and oxygen [66-67]. Non-enzymatic antioxidants, such as reduced glutathione, vitamins C and E, and dietary polyphenols, provide additional buffering capacity against ROS [68]. In diabetes, the activity and expression of these antioxidant systems are significantly diminished. Persistent oxidative stress leads to inactivation of antioxidant enzymes through oxidative modification, while reduced NADPH availability limits glutathione regeneration [68]. Circulating and intracellular levels of glutathione and vitamin antioxidants are frequently depleted, reflecting both increased consumption and impaired recycling [69]. As a result, the antioxidant network becomes progressively weakened, allowing ROS to accumulate and exert cytotoxic effects.

2.3 Interplay with Inflammation and Metabolic Stress

Oxidative stress in diabetes is closely intertwined with chronic low-grade inflammation [20]. Excess ROS activates redox-sensitive transcription factors such as NF- κ B and mitogen-activated protein kinases, which drive the expression of pro-inflammatory cytokines, including tumor necrosis factor- α and interleukin-6 [21]. These cytokines exacerbate insulin resistance and further impair antioxidant gene expression, reinforcing oxidative stress [22]. Metabolic stress, inflammation, and redox imbalance thus form a self-perpetuating cycle in diabetes [23]. Oxidative stress amplifies inflammatory signaling, inflammation disrupts insulin action and antioxidant defenses, and impaired glucose metabolism sustains ROS overproduction. This interconnected network underlies much of the immune dysfunction and tissue damage observed in diabetic individuals.

3. Consequences for Immune Surveillance

3.1 Innate Immune Dysfunction

The innate immune system constitutes the body's first and most immediate defense against invading pathogens and damaged or transformed cells. In diabetes, sustained oxidative stress profoundly alters the function of innate immune cells, compromising their protective capacity. Neutrophils, which play a critical role in early antimicrobial defense, exhibit impaired chemotaxis, reduced phagocytic activity, and diminished oxidative burst capacity under hyperglycemic and pro-oxidative conditions [24]. Excessive ROS disrupts cytoskeletal organization and

intracellular signaling in neutrophils, limiting their ability to migrate effectively to sites of infection and eliminate pathogens [25].

Macrophage function is also significantly altered in the diabetic milieu [26]. Oxidative stress promotes polarization toward a pro-inflammatory M1 phenotype, characterized by heightened production of tumor necrosis factor- α , interleukin-1 β , and other inflammatory mediators [27]. While this phenotype supports pathogen killing, its persistence interferes with the transition to anti-inflammatory and tissue-repairing M2 macrophages, resulting in unresolved inflammation [28]. This imbalance contributes to chronic inflammatory states commonly observed in diabetes and impairs effective immune resolution.

Dendritic cells, which bridge innate and adaptive immunity, are similarly affected by redox imbalance [29]. Excessive ROS interferes with antigen uptake, processing, and presentation, reducing the efficiency of T-cell priming [30]. Collectively, these innate immune defects weaken early immune surveillance and contribute to the increased frequency and severity of bacterial, fungal, and viral infections observed in individuals with diabetes.

3.2 Adaptive Immune Dysfunction

Adaptive immune responses are also sensitive to oxidative stress and metabolic dysregulation [31]. T lymphocytes rely on tightly regulated redox signaling for activation, proliferation, and differentiation. In diabetes, excessive ROS disrupts intracellular signaling cascades downstream of the T-cell receptor, leading to reduced proliferative capacity and impaired cytokine production [32]. Oxidative damage may also promote premature T-cell senescence and apoptosis, further diminishing cellular immunity.

B lymphocyte function is likewise compromised. Chronic hyperglycemia and oxidative stress interfere with B-cell activation and antibody class switching, potentially reducing the quality and durability of humoral immune responses [33]. These defects weaken immunological memory and vaccine responsiveness. Together, impairments in innate and adaptive immunity undermine coordinated immune surveillance, leaving diabetic individuals vulnerable to infection and impaired immune regulation.

4. Tissue Integrity and Diabetes Complications

Oxidative stress and declining antioxidant defenses exert widespread effects on tissue structure and function in diabetes [34]. Persistent ROS accumulation damages cellular lipids, proteins, and nucleic acids, disrupting normal cellular architecture and signaling pathways across multiple organ systems.

4.1 Endothelial Dysfunction and Vascular Damage

The vascular endothelium is particularly susceptible to oxidative injury. Excessive ROS reduces nitric oxide bioavailability by promoting its rapid degradation, impairing endothelium-dependent vasodilation [35]. This endothelial dysfunction represents an early and central event in diabetic vascular disease, contributing to increased vascular tone, platelet activation, and leukocyte adhesion. Oxidative stress also activates matrix metalloproteinases, leading to degradation of extracellular matrix components and destabilization of vascular walls [36]. Concurrent oxidation of low-density lipoproteins accelerates atherogenesis, increasing the risk of macrovascular complications such as coronary artery disease and stroke [36].

4.2 Microvascular Complications

Chronic oxidative stress plays a pivotal role in diabetes-associated microvascular complications. In the retina, ROS damage capillary endothelial cells and pericytes, increasing vascular permeability and promoting pathological neovascularization, hallmark features of diabetic retinopathy [37]. In the kidney, oxidative injury to glomerular endothelial cells, podocytes, and mesangial cells disrupts the filtration barrier, leading to albuminuria and progressive diabetic nephropathy [38]. Peripheral nerves are similarly affected, as oxidative stress impairs neuronal metabolism and microvascular blood flow, resulting in diabetic neuropathy characterized by sensory loss, pain, and autonomic dysfunction.

4.3 Impaired Wound Healing

Defective wound healing is a clinically significant consequence of oxidative stress in diabetes. Excess ROS impairs fibroblast proliferation, collagen deposition, and angiogenesis, all of which are essential for tissue repair [39]. Simultaneously, immune cell dysfunction and poor perfusion increase susceptibility to infection. These factors converge to delay healing and promote chronic non-healing wounds, such as diabetic foot ulcers, which are a major cause of morbidity and limb amputation in diabetic patients.

CONCLUSION

The decline in antioxidant networks in diabetes is a pivotal factor linking metabolic dysfunction to immune impairment and structural tissue damage. Persistent oxidative stress undermines immune surveillance and contributes to the pathogenesis of diabetic complications through endothelial damage, chronic inflammation, and direct molecular injury. Although therapeutic strategies aimed at restoring redox balance show potential, more

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

research is needed to translate mechanistic insights into clinically effective interventions. A holistic approach integrating metabolic control, targeted therapies, and lifestyle optimization—offers the most promise for preserving immune competence and tissue integrity in individuals with diabetes.

REFERENCES

1. Uti DE, Atangwho IJ, Alum EU, Egba SI, Ugwu OPC, Ikechukwu GC. Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. *Natural Product Communications*. 2025;20(3). doi:10.1177/1934578x251323393
2. Ugwu, O.P.C., Kungu, E., Inyangat, R., Obeagu, E. I., Alum, E. U., Okon, M. B., Subbarayan, S. and Sankarapandian, V. Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. *INOSR Experimental Sciences*. 2023; 12(2):214–224. <https://doi.org/10.59298/INOSRES/2023/2.17.1000>.
3. Ugwu, O. P. C., Alum, E. U. and Uhama, K. C. (2024). Dual Burden of Diabetes Mellitus and Malaria: Exploring the Role of Phytochemicals and Vitamins in Disease Management. *Research Invention Journal of Research in Medical Sciences*. 3(2):38–49.
4. Godfrey Ogochukwu Ezema, Ndukaku Yusuf Omeh, Egba Simeon Ikechukwu, Ejiofor C Agbo, Adachukwu Ada Ikeyiand Emmanuel Ifeanyi Obeagu. Evaluation of Biochemical Parameters of Patients with Type 2 Diabetes Mellitus Based on Age and Gender in Umuahia (2023) *Asian Journal of Dental and Health Sciences* 2023; 3(2):32–36
5. Uhuo E N, Egba S I, Nwuke P C, Obike C A and Kelechi G K. Antioxidative properties of *Adansonia digitata* L. (baobab) leaf extract exert protective effect on doxorubicin induced cardiac toxicity in Wistar rats. *Clinical Nutrition Open Science* 2022; 45:3–16
6. Ugwu, CE., Sure, SM., Dike, CC., Okpoga, NA and Egba, SI. Phytochemical and *in vitro* antioxidant activities of methanol leave extract of *Alternanthera basiliiana*. *Journal of Pharmacy Research*, 2018; 12(6): 835–839
7. Ochulor Okechukwu C., Njoku Obioma U., Uroko Robert I and Egba Simeon I. Nutritional composition of *Jatropha tanjorensis* leaves and effects of its aqueous extract on carbon tetrachloride induced oxidative stress in male Wistar albino rats. *Biomedical Research* 2018; 29(19): 3569–3576
8. Orji, O.U., Awoke, N.J., Obasi, D.O., Aja, P.M., Ezeani, N.N., Umoru, G.U., Ogbu, P.N., Udoudoh, M.P., Ogbu, C.O., Oodo, S.I., Ibiam, U.A. The Therapeutic Role of Gastrodin in Combating Insulin Resistance, Inflammation, and Oxidative Stress Induced by Bisphenol-A. *Natural Product Communications*. 2024;19(12). doi:10.1177/1934578X241310096
9. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.A. (2025). Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. *Obesity Medicine*, 2025; 100622. <https://doi.org/10.1016/j.obmed.2025.100622>
10. Ogugua, Victor N., Njoku, Obioma U., Egba, Simeon I., Uroko, Robert I and Ignatius Glory. In vitro study of nutritional and antioxidant properties of methanol extract of *Nauclea latifolia* root bark. *Biomedical Research*, 2018; 29(21): 3766–3773
11. González P, Lozano P, Ros G, Solano F. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. *Int J Mol Sci*. 2023 May 27;24(11):9352. doi: 10.3390/ijms24119352. PMID: 37298303; PMCID: PMC10253853.
12. Khalid M, Petroianu G, Adem A. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. *Biomolecules*. 2022 Apr 4;12(4):542. doi: 10.3390/biom12040542. PMID: 35454131; PMCID: PMC9030615.
13. Zhang Y, Zhang Z, Tu C, Chen X, He R. Advanced Glycation End Products in Disease Development and Potential Interventions. *Antioxidants*. 2025; 14(4):492. <https://doi.org/10.3390/antiox14040492>
14. Papachristoforou E, Lambadiari V, Maratou E, Makrilakis K. Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications. *J Diabetes Res*. 2020 Oct 12;2020:7489795. doi: 10.1155/2020/7489795. PMID: 33123598; PMCID: PMC7585656.
15. Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, Squadrito F, Altavilla D, Bitto A. Oxidative Stress: Harms and Benefits for Human Health. *Oxid Med Cell Longev*. 2017;2017:8416763. doi: 10.1155/2017/8416763. Epub 2017 Jul 27. PMID: 28819546; PMCID: PMC5551541.
16. Hong Y, Boiti A, Vallone D, Foulkes NS. Reactive Oxygen Species Signaling and Oxidative Stress: Transcriptional Regulation and Evolution. *Antioxidants*. 2024; 13(3):312.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

- <https://doi.org/10.3390/antiox13030312>
17. Meulmeester FL, Luo J, Martens LG, Mills K, van Heemst D, Noordam R. Antioxidant Supplementation in Oxidative Stress-Related Diseases: What Have We Learned from Studies on Alpha-Tocopherol? *Antioxidants (Basel)*. 2022 Nov 24;11(12):2322. doi: 10.3390/antiox11122322. PMID: 36552530; PMCID: PMC9774512.
 18. Tan BL, Norhaizan ME, Liew WP, Sulaiman Rahman H. Antioxidant and Oxidative Stress: A Mutual Interplay in Age-Related Diseases. *Front Pharmacol*. 2018 Oct 16;9:1162. doi: 10.3389/fphar.2018.01162. PMID: 30405405; PMCID: PMC6204759.
 19. Hajam YA, Rani R, Ganie SY, Sheikh TA, Javaid D, Qadri SS, Pramodh S, Alsulimani A, Alkhanani MF, Harakeh S, et al. Oxidative Stress in Human Pathology and Aging: Molecular Mechanisms and Perspectives. *Cells*. 2022; 11(3):552. <https://doi.org/10.3390/cells11030552>
 20. Oguntibeju OO. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. *Int J Physiol Pathophysiol Pharmacol*. 2019 Jun 15;11(3):45-63. PMID: 31333808; PMCID: PMC6628012.
 21. Weinberg Sibony R, Segev O, Dor S, Raz I. Overview of oxidative stress and inflammation in diabetes. *J Diabetes*. 2024 Oct;16(10):e70014. doi: 10.1111/1753-0407.70014. PMID: 39435991; PMCID: PMC11494684.
 22. Burgos-Morón E, Abad-Jiménez Z, Martínez de Marañón A, Iannantuoni F, Escribano-López I, López-Domènech S, Salom C, Jover A, Mora V, Roldan I, et al. Relationship between Oxidative Stress, ER Stress, and Inflammation in Type 2 Diabetes: The Battle Continues. *Journal of Clinical Medicine*. 2019; 8(9):1385. <https://doi.org/10.3390/jcm8091385>
 23. Dawi J, Misakyan Y, Affa S, Kades S, Narasimhan A, Hajjar F, Besser M, Tumanyan K, Venketaraman V. Oxidative Stress, Glutathione Insufficiency, and Inflammatory Pathways in Type 2 Diabetes Mellitus: Implications for Therapeutic Interventions. *Biomedicines*. 2024 Dec 26;13(1):18. doi: 10.3390/biomedicines13010018. PMID: 39857603; PMCID: PMC11762874.
 24. Lehman HK, Segal BH. The role of neutrophils in host defense and disease. *J Allergy Clin Immunol*. 2020 Jun;145(6):1535-1544. doi: 10.1016/j.jaci.2020.02.038. Epub 2020 Apr 10. PMID: 32283205; PMCID: PMC8912989.
 25. Rosales C. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? *Front Physiol*. 2018 Feb 20;9:113. doi: 10.3389/fphys.2018.00113. PMID: 29515456; PMCID: PMC5826082.
 26. Aitcheson SM, Frentiu FD, Hurn SE, Edwards K, Murray RZ. Skin Wound Healing: Normal Macrophage Function and Macrophage Dysfunction in Diabetic Wounds. *Molecules*. 2021 Aug 13;26(16):4917. doi: 10.3390/molecules26164917. PMID: 34443506; PMCID: PMC8398285.
 27. Rong B, Jiang H, Zhu W, Yang G, Zhou X, Lyu Z, Li X, Zhang J. Unraveling the role of macrophages in diabetes: Impaired phagocytic function and therapeutic prospects. *Medicine (Baltimore)*. 2025 Feb 21;104(8):e41613. doi: 10.1097/MD.00000000000041613. PMID: 39993124; PMCID: PMC11856964.
 28. Barry SE, Sawka A, Maldari A, Inauen J, LaBroome S, Geake JB. Macrophage Dysfunction in Tuberculosis–Diabetes Mellitus Comorbidity: A Scoping Review of Immune Dysregulation and Disease Progression. *Diabetology*. 2025; 6(5):35. <https://doi.org/10.3390/diabetology6050035>
 29. Sun L, Wang X, Saredy J, Yuan Z, Yang X, Wang H. Innate-adaptive immunity interplay and redox regulation in immune response. *Redox Biol*. 2020 Oct;37:101759. doi: 10.1016/j.redox.2020.101759. Epub 2020 Oct 10. PMID: 33086106; PMCID: PMC7575795.
 30. Dagah OMA, Silaa BB, Zhu M, Pan Q, Qi L, Liu X, Liu Y, Peng W, Ullah Z, Yudas AF, Muhammad A, Zhang X, Lu J. Exploring Immune Redox Modulation in Bacterial Infections: Insights into Thioredoxin-Mediated Interactions and Implications for Understanding Host-Pathogen Dynamics. *Antioxidants (Basel)*. 2024 Apr 29;13(5):545. doi: 10.3390/antiox13050545. PMID: 38790650; PMCID: PMC11117976.
 31. Forcados GE, Muhammad A, Oladipo OO, Makama S, Meseko CA. Metabolic Implications of Oxidative Stress and Inflammatory Process in SARS-CoV-2 Pathogenesis: Therapeutic Potential of Natural Antioxidants. *Front Cell Infect Microbiol*. 2021 May 26;11:654813. doi: 10.3389/fcimb.2021.654813. PMID: 34123871; PMCID: PMC8188981.
 32. Liu S, Liu J, Wang Y, Deng F, Deng Z. Oxidative Stress: Signaling Pathways, Biological Functions, and Disease. *MedComm (2020)*. 2025 Jul 1;6(7):e70268. doi: 10.1002/mco2.70268. PMID: 40599237; PMCID: PMC12209598.
 33. Bishop NH, Nelsen MK, Beard KS, Coulombe M, Gill RG. Differential Impact of Chronic Hyperglycemia

- on Humoral Versus Cellular Primary Alloimmunity. *Diabetes*. 2017 Apr;66(4):981-986. doi: 10.2337/db16-0218. Epub 2017 Jan 9. PMID: 28069641; PMCID: PMC5360296.
34. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. *Cardiovasc Diabetol*. 2005 Apr 29;4:5. doi: 10.1186/1475-2840-4-5. PMID: 15862133; PMCID: PMC1131912.
35. Lubos E, Handy DE, Loscalzo J. Role of oxidative stress and nitric oxide in atherothrombosis. *Front Biosci*. 2008 May 1;13:5323-44. doi: 10.2741/3084. PMID: 18508590; PMCID: PMC2617738.
36. Alum, E. U. (2025). Role of phytochemicals in cardiovascular disease management: Insights into mechanisms, efficacy, and clinical application. *Phytomedicine Plus*, 5(1),100695. <https://doi.org/10.1016/j.phyplu.2024.100695>.
37. He W, Tang P, Lv H. Targeting oxidative stress in diabetic retinopathy: mechanisms, pathology, and novel treatment approaches. *Front Immunol*. 2025 Jun 16;16:1571576. doi: 10.3389/fimmu.2025.1571576. PMID: 40589740; PMCID: PMC12207546.
38. Wang W, Lo ACY. Diabetic Retinopathy: Pathophysiology and Treatments. *International Journal of Molecular Sciences*. 2018; 19(6):1816. <https://doi.org/10.3390/ijms19061816>
39. Ukaegbu K, Allen E, Svoboda KKH. Reactive Oxygen Species and Antioxidants in Wound Healing: Mechanisms and Therapeutic Potential. *Int Wound J*. 2025 May;22(5):e70330. doi: 10.1111/iwj.70330. PMID: 40288766; PMCID: PMC12034374.
40. Ugwu OPC, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Ethanol root extract and fractions of *Sphenocentrum jollyanum* abrogate hyperglycaemia and low body weight in streptozotocin-induced diabetic Wistar albino rats. *RPS Pharm Pharmacol Rep*. 2023;2(2):rqad010.
41. Ugwu OPC, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Anti-nutritional and gas chromatography-mass spectrometry (GC-MS) analysis of ethanol root extract and fractions of *Sphenocentrum jollyanum*. *RPS Pharm Pharmacol Rep*. 2023;2(2):rqad007.
42. Ugwu OPC, Amasiorah VI. The in vitro antioxidant potentials of the crude ethanol root extract and fractions of *Sphenocentrum jollyanum*. *INOSR Appl Sci*. 2020;6(1):125-33.
43. Ugwu OPC, Amasiorah VI. The effects of the crude ethanol root extract and fractions of *Sphenocentrum jollyanum* on hematological indices and glycosylated haemoglobin of streptozotocin-induced diabetic rats. *INOSR Sci Res*. 2020;6(1):61-74.
44. Ugwu OPC, Amasiorah VI. The effects of crude ethanol root extract and fractions of *Sphenocentrum jollyanum* on the lipid profile of streptozotocin-induced diabetic Wistar albino rats. *IDOSR J Biol Chem Pharm*. 2020;5(1):36-46.
45. Ugwu OPC, Amasiorah VI. The in vivo antioxidant potentials of the crude ethanol root extract and fractions of *Sphenocentrum jollyanum* on oxidative stress indices in streptozotocin-induced diabetic rats. *IDOSR J Biol Chem Pharm*. 2020;5(1):26-35.
46. Ugwu OPC, Onyeneke EC, Igwenyi IO, Aja PM, Okon MB. The effects of crude ethanol root extract and fractions of *Sphenocentrum jollyanum* on liver and kidney function parameters of streptozotocin-induced diabetic Wistar albino rats. *IAA J Sci Res*. 2018;4(1):75-90.
47. Aja PM, Igwenyi IO, Ugwu OPC, Orji OU, Alum EU. Evaluation of anti-diabetic effect and liver function indices of ethanol extracts of *Moringa oleifera* and *Cajanus cajan* leaves in alloxan induced diabetic albino rats. *Global Vet*. 2015;14(3):439-47.
48. Offor CE, Ugwu OPC, Alum EU. The anti-diabetic effect of ethanol leaf-extract of *Allium sativum* on albino rats. *Int J Pharm Med Sci*. 2014;4(1):1-3.
49. Ugwu OPC, Alum EU, Uhama KC. Dual burden of diabetes mellitus and malaria: exploring the role of phytochemicals and vitamins in disease management. *Res Invent J Res Med Sci*. 2024;3(2):38-49.
50. Obeagu EI, Ugwu OPC, Alum EU. Poor glycaemic control among diabetic patients: a review on associated factors. *Newport Int J Res Med Sci*. 2023;3(1):30-3.
51. Alum EU, Ugwu OPC, Obeagu EI, Ugwu CN, Uti DE, Samson AO, et al. Nutritional care in diabetes mellitus: a comprehensive guide. *Int J Innov Appl Res*. 2023;11(12):16-25.
52. Alum EU, Ugwu OPC, Obeagu EI, Uti DE, Egba SI, Alum BN. Managing the dual burden: addressing mental health in diabetes care. *Elite J Med Sci*. 2024;2(6):1-9.
53. Alum EU, Obeagu EI, Ugwu OPC, Alum BN, Arinze ED, Ukaidi CUA. Exploring the differential impacts of intermittent fasting on men and women. *Elite J Health Sci*. 2024;2(5):37-44.

54. Obeagu EI, Scott GY, Amekpor F, Ugwu OPC, Alum EU. Covid-19 infection and diabetes: a current issue. *Int J Innov Appl Res.* 2023;11(1):25–30.
55. Alum EU, Ugwu OPC. Beyond pregnancy: understanding the long-term implications of gestational diabetes mellitus. *INOSR Sci Res.* 2024;11(1):63–71.
56. Ugwu OPC, Ugwu MN, Basajja M, Anyanwu CN, Ogenyi FC, Ugwu CN, et al. Targeting gut microbial signatures to personalize obesity treatment: integrating microbiome-based stratification into precision medicine. *Obes Med.* 2025;57:100639.
57. Ugwu OPC, Ogenyi FC, Ugwu CN, Ugwu MN. Gut microbiota-derived metabolites as early biomarkers for childhood obesity: a policy commentary from urban African populations. *Obes Med.* 2025;57:100641.
58. Ugwu OPC, Swase DT, Okon MB, Mujinya R. Traditional East African medicinal plants as modulators of gut microbiota in obesity-associated diabetes: a short communication. *Obes Med.* 2025;654:00654.
59. Uti DE, Omang WA, Alum EU, Ugwu OPC, Wokoma MA, Oplekwu RI, et al. Targeting CD44-hyaluronic acid signalling in obesity treatment: insights from small molecules and nanobioconjugates. *Nutr Metab Insights.* 2026;19:11786388251408961.
60. Uti DE, Omang WA, Alum EU, Atangwho IJ, Ugwu OPC, Wokoma MA, et al. Combined hyaluronic acid nanobioconjugates impair CD44-signaling for effective treatment against obesity: a review of comparison with other actors. *Int J Nanomedicine.* 2025;20:10101–26.
61. Uti DE, Egbung JE, Alum EU, Bawa I, Ugwu OPC, Egba SI, et al. Nanotechnology-enabled targeted delivery of incretin therapies for the treatment of obesity and metabolic disorders. *Obes Med.* 2026:100712.
62. Ugwu OPC, Eke MC, Ogenyi FC, Basajja M, Ugwu CN. Could chronic exposure to nocturnal artificial light pollution be an overlooked driver of urban obesity and metabolic syndrome? *Med Hypotheses.* 2025;205:111819.
63. Alum EU, Izah SC, Uti DE, Ugwu OPC, Betiang PA, Basajja M, et al. The ketogenic diet in obesity management: friend or foe? *Cell Biochem Biophys.* 2025.
64. Udeh SMC, Nwodo OFC, Yakubu OE, Parker EJ, Egba SI, Omenyi SN, et al. Effects of methanol extract of *Gongronema latifolium* leaves on glycaemic responses to carbohydrate diets in streptozotocin-induced diabetic rats. *J Biol Sci.* 2022;22:70–9.
65. Ugwu OPC, Alum EU, Obeagu EI, Okon MB. Effect of ethanol leaf extract of *Chromolaena odorata* on lipid profile of streptozotocin-induced diabetic Wistar albino rats. *IAA J Biol Sci.* 2023;10(1):109–17.
66. Ugwu OPC, Alum EU, Obeagu EI, Okon MB. Effect of ethanol leaf extract of *Chromolaena odorata* on hepatic markers in streptozotocin-induced diabetic Wistar albino rats. *IAA J Appl Sci.* 2023;9(1):46–56.
67. Aja PM, Ibekwe VI, Ekpono EU, Ugwu PC, Ugwu OPC. Effect of ethanol extract of *Cajanus cajan* leaf on plasma lipid level in albino rats. *Int J Curr Res Acad Rev.* 2015;3(1):161–7.
68. Obeagu EI, Ugwu OPC. Overweight and obesity among adolescents: a review. *Newport Int J Res Med Sci.* 2023;3(1):25–9.
69. Obeagu EI, Ugwu OPC. Insulin self-medication among diabetic patients: a review of associated factors. *Newport Int J Res Med Sci.* 2023;3(1):21–4.

CITE AS: Ivan Mutebi (2026). Diabetes-Associated Decline in Antioxidant Networks: Consequences for Immune Surveillance and Tissue Integrity. NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 7(2):23-29.
<https://doi.org/10.59298/NIJBAS/2026/7.2.2329>